REG - Verici Dx PLC - Positive Q1 Trading Update

Verici DxAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260416:nRSP6416Aa&default-theme=true

RNS Number : 6416A  Verici Dx PLC  16 April 2026

 

Verici Dx plc

("Verici Dx" or the "Company")

 

Positive Q1 Trading Update

 

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, provides a trading update demonstrating strong momentum for
the three months ended 31 March 2026 (Q1 '26).

 

Further to the year-end update (https://vericidx.com/investors/rns/) provided
on 5 February 2026, the Company has delivered strong growth in Q1 '26.
Tutivia(TM) testing volumes increased quarter-on-quarter by 32% to 392 (Q4
'25: 296), significantly ahead of management expectations. Year-on-year Q1
testing volumes were up 34% (Q1 '26 vs Q1 '25). The average reimbursement rate
remains in line with management expectations.

 

Seven new transplant centres ordered tests during the first quarter of the new
financial year, and a second centre now includes Tutivia(TM) in its clinical
protocols for patients during their treatment pathway.

 

Relationships with key transplant centres continue to deepen and a number of
onboarded centres have become repeat ordering centres. Six of the repeat
ordering centres grew volumes by more than 20%, including two of the largest
centres by testing volumes increasing by more than 30%. The number of centres
using Tutivia(TM) now represent 20% of annual kidney transplants in the US
(based upon UNOS.org data)

 

In addition to the Medicare coverage noted last year
(https://www.londonstockexchange.com/news-article/VRCI/verici-receives-medicare-coverage-for-tutivia/16984309)
, Tutivia is now approved in an additional two State Medicaid programmes
(total to date, 17 States) facilitating ease and timeliness of payment
processing.

 

In the period, Keith Gilliard was also appointed as Senior Director of Sales
to lead the sales team, in a non-Board position. Keith has previously held
senior sales roles at Waters Medical Systems, OrganOx Inc., CareDx, Inc.,
Bristol-Myers Squibb and Novartis Pharmaceuticals. This wealth of experience
will be integral in continuing the strong momentum that the Company has
established in Q1, with the onboarding of multiple new centres.

 

The Company will announce its full year results for the year ended 31 December
2025 by the end of May 2026.

 

Sara Barrington, Chief Executive Officer, said: "We are very pleased to see
further adoption of Tutivia™ and strong testing volume acceleration in the
opening quarter of the year, building on the substantial growth we saw in
FY25. Together with our ongoing progress in business development, this
underpins our confidence in achieving further successful commercial traction
across the rest of 2026 and beyond."

 

 

 Verici Dx plc                                 www.vericidx.com (https://vericidx.com/)

 Sara Barrington, CEO                          Via Walbrook PR

 Singer Capital Markets (Nominated adviser, Joint Broker)                     Tel: +44 (0)20 7496 3000
 Phil Davies / Jalini Kalaravy

 Oberon Capital (Joint Broker)                 Tel: +44 (0)20 3179 0500
 Mike Seabrook / Adam Pollock

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com
 Alice Woodings / Rachel Broad                 Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393

 

Verici Dx

Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care
for transplant patients. The company combines multiomic analysis with
proprietary artificial intelligence to deliver predictive, actionable,
data-driven intelligence that reflects the complexity and heterogeneity of
transplant patients, enabling clinicians to optimize therapy, guide biopsy
decisions, and stratify risk with greater confidence.

 

Operating at the intersection of laboratory and data science, Verici Dx
develops complex models that answer the clinical questions that matter most
with unrivaled clarity and precision. All tests are built to rigorous
scientific standards, validated across inclusive, and real-world patient
populations to ensure clinical relevance and reliability. Verici Dx's lead
product, Tutivia™, is a post-kidney transplant test focused on early
detection of acute rejection.

 

The company is UK headquartered in Cardiff for the UK, and in Franklin,
Tennessee for the U.S. For more information, please visit
https://vericidx.com/ (https://vericidx.com/) and follow us on LinkedIn
(https://www.linkedin.com/company/verici-dx/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTEAKLSFEAKEFA



            Copyright 2019 Regulatory News Service, all rights reserved